SCHEMBL19992223

SCHEMBL19992223

C[C@@H](N)CNc1ccc2cc(C(C)(C)O)c3nc4cc(OC(C)(C)c5cc6ccc(N7CCC[C@H](N)C7)nc6n6c5nc5ccccc56)ccc4n3c2n1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 2/20 0.32
▸ PIM2 Q9P1W9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18057400 0.82 MAP4K4 (0.39) PIM1PIM2
SCHEMBL18057399 0.79 KDM4E (0.38) —
SCHEMBL18057404 0.77 PDE10A (0.39) PIM1PIM2
SCHEMBL19365030 0.73 SMN1; SMN2 (0.41) —
SCHEMBL23160988 0.71 DPP4 (0.38) PIM1PIM2
SCHEMBL19992116 0.70 KDM4E (0.39) —
SCHEMBL20078427 0.70 CAMK1D (0.43) —
SCHEMBL18057407 0.68 PDE10A (0.42) —
SCHEMBL23161001 0.68 SYK (0.37) —
SCHEMBL18057401 0.68 POLR1A (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590134-B2 Compositions, uses and methods for making them Pimera, Inc. (US) 2020-03-17 — — US disclosed
US-20180079750-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM UNITED STATES GOVERNMENT 2018-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590134-B2 Compositions, uses and methods for making them BAX, CASP3, BCL2 PIM1 3033/4885PIM2 3662/4885
US-20180079750-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM BAX, CASP3, BCL2 PIM1 2987/4885PIM2 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback